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Abstract
Background: Exercise-induced muscle damage (EIMD) results in transient muscle inflammation, strength loss,
muscle soreness and may cause subsequent exercise avoidance. Omega-3 (n-3) supplementation may minimise
EIMD via its anti-inflammatory properties, however, its efficacy remains unclear.
Methods: Healthy males (n = 14, 25.07 ± 4.05 years) were randomised to 3 g/day n-3 supplementation (N-3, n = 7) or
placebo (PLA, n = 7). Following 4 weeks supplementation, a downhill running protocol (60 min, 65% V̇O2max, − 10%
gradient) was performed. Creatine kinase (CK), interleukin (IL)-6 and tumour necrosis factor (TNF)-α, perceived
muscle soreness, maximal voluntary isometric contraction (MVIC) and peak power were quantified pre, post, and 24,
48 and 72 h post-EIMD.
Results: Muscle soreness was significantly lower in N-3 vs PLA group at 24 h post-EIMD (p = 0.034). IL-6 was
increased in PLA (p = 0.009) but not in N-3 (p = 0.434) following EIMD, however, no significant differences were
noted between groups. Peak power was significantly suppressed in PLA relative to pre-EIMD but not in N-3 group
at 24 h post-EIMD. However, no significant difference in peak power output was observed between groups. MVIC,
CK and TNF-α were altered by EIMD but did not differ between groups.
Conclusion: N-3 supplementation for 4 weeks may successfully attenuate minor aspects of EIMD. Whilst not
improving performance, these findings may have relevance to soreness-associated exercise avoidance.
Keywords: Omega-3, Supplementation, Ergogenic aid, Eccentric exercise, Muscle damage, EIMD, DOMS, Recovery,
Inflammation, Performance
Background
The recovery from vigorous athletic performance con-
cerns many groups of people, from high performance
athletes to recreationally active individuals. Eccentric ex-
ercise, especially novel or high-force eccentric protocols,
can produce substantial muscle fibre damage [1, 2]. Such
vigorous-intensity exercise may lead to exercise-induced
muscle damage (EIMD) [3]. Symptoms of EIMD include
pain, swelling, muscle strength and power loss, reduced
range of motion (ROM), delayed onset muscle soreness
(DOMS) and impaired recovery [4, 5]; resulting in im-
pairment of exercise performance [6]. Functionally,
muscle strength is reduced by ~ 20 to 50% immediately
and post-exercise can take between 2 to 7 days to fully
recover [7]. Systemically, EIMD is paralleled by an in-
flammatory response involving many mediators, such as
interleukin − 1 receptor antagonist (IL-1ra), interleukin
(IL)-6, IL-10 and acute phase proteins [8], and a release
of muscle specific creatine kinase [1, 9]. Strategies to re-
duce muscle damage and inflammation following EIMD
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can therefore be of use to individuals interested in in-
creasing their rate of recovery and maintaining
performance.
Omega-3 polyunsaturated fatty acids (n-3 PUFA) have
a double bond that is closest to the methyl terminus
(−CH3) of the acyl chain [10]. N-3 PUFA are incorpo-
rated into phospholipids, altering cell membranes, which
typically contain a high proportion of arachidonic acid
(AA). This results in increased accumulation of eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA)
and at the parallel decline of AA; and potentially blunt-
ing reactive oxygen species (ROS) and inflammatory
cytokine production [10]. Anti-inflammatory mediators
derived from n-3 PUFA and its main bioactive fatty
acids, such as EPA and DHA, have been recognised
along with their mechanism of their action [10]. It has
been suggested that n-3 PUFA may prove a viable strat-
egy to attenuate muscle inflammation and improve func-
tional recovery following high-intensity exercise [11].
One of the connections between n-3 PUFA and muscle
inflammation is via down-regulation of pro-
inflammatory cytokines, such as TNF-α and IL-6, re-
duced production of AA and ROS, consequently, result-
ing in a decrease in the inflammatory response [12].
Increasing evidence suggests that n-3 supplementation
impairs pro-inflammatory cytokines and ROS produc-
tion, and hence may show a direct relationship between
intense exercise recovery and markers of inflammation
[12, 13]. Although animal studies have shown mixed re-
sults when evaluating the efficacy of n-3 supplementa-
tion on muscle damage, exercise metabolism and
exercise performance; human studies have demonstrated
that physiological parameters that are linked to im-
proved physical performance and oxygen utilisation,
such as blood flow during exercise, can be augmented by
dietary n-3 PUFA [11, 14]. Tarbinian et al. [15], Jouris
et al. [16] and Jakeman et al. [17] have shown a pain re-
duction following EIMD with n-3 supplementation. A
recent meta-analysis [18] also concluded that n-3 sup-
plementation could alleviate DOMS after eccentric exer-
cise. Additionally, Atashak et al. [19] reported
substantial reduction in CK and in C-reactive protein
after lower body resistance exercise following 1 week of
540 mg EPA and 360 mg DHA. Further, other studies
[20, 21] have demonstrated that n-3 supplementation
has a positive effect on eccentric exercise protocols by
reducing the concentrations of IL-6 and TNF-α. How-
ever, mixed results have been reported to date, with
others [22, 23] observing no effect of n-3 supplementa-
tion on exercise-induced inflammatory and muscle dam-
age markers, and functional markers, such as maximal
voluntary contraction (MVC) and DOMS.
It remains unclear whether n-3 supplementation has
any beneficial effect in blunting the effects of EIMD,
either by increasing the rate of recovery of functional
performance, by reducing circulating pro-inflammatory
cytokines, or both. Due to this lack of clarity in the lit-
erature, the aim of the current study was to add evi-
dence by assessing the effect of n-3 supplementation on
EIMD following a downhill running bout. It was
hypothesised that 3 g of n-3 supplementation for 4 weeks
would attenuate muscle inflammation following EIMD
which subsequently would decrease the recovery time,
and thus improve exercise performance.
Methods
Participants
Ethical approval was obtained by the College of Liberal
of Arts and Sciences Research Ethics Committee, Uni-
versity of Westminster (ETH1617–0182). All work
herein conforms to the standards set by the Declaration
of Helsinki of 1975. Written informed consent was ob-
tained from all participants prior to their participation.
A total of 23 healthy, physically active males (self-re-
ported: 4–5 times weekly structured exercise) aged 18–
35 years of age were recruited to participate in this ex-
perimental study. Following withdrawals (n = 9; inability
to attend all visits, injury or illness outside of trials or in-
ability to complete downhill protocol), 14 participants
(25.07 ± 4.05 years of age) completed the protocol and
are included in the analysis below.
Participants were required to refrain from any struc-
tured exercise for 48 h, and from alcohol and caffeine
24 h prior to baseline visit and EIMD protocol. They
were also asked to refrain from eccentric strenuous exer-
cise during the 5 weeks of the study as well as in the fol-
lowing 72 h after the muscle-damaging exercise bout.
Exclusion criteria included age (outside 18–35 age
range), smoking, sex, taking any medication (e.g. non-
steroidal anti-inflammatory drugs), and consuming fish
oil supplements < 6 months prior to commencing the
study and the presence of any known immune, cardio-
vascular or metabolic disease. To further confirm partic-
ipants were free from upper respiratory tract infections,
they completed an illness-specific questionnaire
(WURSS-21) [24]. Additionally, participants were free
from any pain or injury as determined by the Physical
Activity Readiness Questionnaire (PAR-Q) pre-exercise
participation screening. Participants were also excluded
if they regularly undertook downhill running or eccen-
tric exercise (e.g. resistance exercise, squats) as part of
their normal training < 6months prior to commencing
the study.
Experimental design
All participants were required to attend the human per-
formance laboratory in the morning on 5 occasions.
During visit 1, in an overnight fasted-state, participants
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performed baseline measurements which included an-
thropometric measurements, a urine sample and a ven-
ous blood sample. Perceived muscle soreness, maximal
voluntary isometric contraction (MVIC) on the leg and
anaerobic peak power via Wingate test were determined
as indirect markers of muscle damage, described fully
below.
Following baseline measurements, participants per-
formed a treadmill V̇O2max test (HP Cosmos Mercury
4.0, Nussdorf-Traunstein, Germany) with expired gases
analysed by an on-line breath-by breath system (Cortex
Metalyser 3B, Biophysik, Leipzig, Germany). The Meta-
lyser was calibrated according to manufacturer’s guide-
lines prior to each test. Following completion of the
V̇O2max test, a 6-min running speed (Vtest) at 65%
V̇O2max verification was performed on a downhill run
at − 10% gradient, as we have previously reported [25].
After baseline testing, participants were single-blind ran-
domised to either N-3 (3 g/day of n-3 PUFA) or PLA
(placebo) group by a computer-generated block
randomization in advance (http://www.randomization.
com).
Two weeks before beginning testing, participants filled
a health questionnaire (WURSS-21) on each of the 14
days preceding trial to ensure that they were free from
common cold symptoms before testing. In visit 2, partic-
ipants reported to the laboratory at 07:00 am having
fasted overnight and performed the EIMD protocol
(downhill running; 60 min at 65% V̇O2max with a − 10%
gradient). All above measurements were repeated prior
to- and immediately-post the EIMD trial. One day be-
fore the visit participants were asked to consume water
based on their body mass (5 mL/kg) [25] before they re-
ported to the laboratory to ensure adequate hydration
before exercise. Identical follow up assessments, except
urine sample, were repeated at visits 3-to-5 (24, 48 and
72 h post-EIMD), during which participants were in a
non-fasted state. An overview of the study design is pre-
sented in Fig. 1.
Hydration status
Urine sample was collected at baseline and pre-EIMD to
assess participants’ hydration status. Hydration was veri-
fied by checking that urine specific gravity (USG) (Atago
MASTER-SUR/Na refractometer, Atago Co., Ltd. Tokyo,
Japan) upon arrival was between 1.001 and 1.029 [26].
Urine colour was also checked by using the validated
urine colour chart (1–8 scale) [26].
Anthropometric measurements
Height (to nearest 0.1 cm) was measured using a wall-
mounted “Harpenden” stadiometer (Holtain Ltd., Cry-
mych, Wales, UK) fitted with a high speed Veeder-Root
counter (Veeder-Root, Elizabethtown, NC, USA) with
participants stood in bare feet, heels together with their
shoulders and buttocks in contact with the stadiometer.
Body weight (to nearest 0.1 kg), BMI and body fat % (to
nearest 0.1%) were measured using BIA (Tanita SC-
330ST, Tokyo, Japan) with participant being fasted and
with an empty bladder.
Supplementation
Omega-3 supplementation consisted of 3 gelatine-coated
capsules per day (1 consumed in the morning, 1 at lunch
and 1 in the evening), each containing 1040mg of n-3
PUFA (715mg of EPA and 286 mg DHA) per capsule
(Maximum Strength Pure Fish Oil, Nature’s Best, UK)
for a total of 3900mg of fish oil daily, containing 3 g of
n-3 PUFA (2145mg of EPA and 858 mg DHA) per day
for a period of 4 weeks. Whilst commonly reported side
Fig. 1 Schematic of experimental procedures: USG, urine specific gravity; BIA, bioelectrical impedance analysis; VAS, visual analogue scale for
delayed-onset muscle soreness; MVIC, maximal voluntary isometric contraction; V̇O2max, maximal oxygen consumption; N-3, omega-3
supplementation group; PLA, placebo group; EIMD, exercise-induced muscle damage. 2nd visit combines both pre and post measurements,
immediately prior and following EIMD stimulus, respectively. A further Wingate test was added on 2nd visit and all follow up visits
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effects of n-3 supplementation, such as unpleasant taste,
heartburn, gastrointestinal discomfort and headache are
usually mild [27], the amount of n-3 provided is in line
with the nutritional recommendations as part of a nor-
mal diet and does not cause any harm or side effects.
Daily supplementation of up to about 5 g/day of n-3
PUFA in a long-term consumption is considered safe by
the European Food Safety Authority (EFSA) [28]. Longer
duration or high doses may affect immune function due
to suppression of inflammatory response [29]. High
doses also might increase bleeding time by reducing
platelet aggregation [29]. The placebo group received
3 × 600 mg capsules per day of collagen (Troo Health-
care, Colchester, UK), consumed in a matching pattern.
Participants were only given 1 week of capsules at a
time. Initially written reminders were sent on a daily
basis to ensure supplementation practices were main-
tained consistent throughout the day. Participants’ com-
pliance also verified by weekly written and oral
reminders, counting remaining capsules at the end of
each week and issuing of future weeks capsules took
place. Further, participants were asked to guess what
group they were at the conclusion of testing with 2 of 7
in placebo and 5 of 7 in N-3 group correctly guessing
the supplementation group.
Diet and activity control
Participants were requested to maintain their usual diet
and physical activity throughout the study. A 48-h food
diary (including 1 day of the week and one weekend
day) was provided to record all foods and drinks con-
sumed prior to the supplementation period starting. Fol-
lowing 4 weeks of supplementation, participants
completed a second 48-h food diary in the 2 days prior
to the EIMD trial. Written and oral reminders were also
provided on a regular basis to ensure diet and exercise
practices were maintained consistent throughout the
study.
Food diaries were analysed using Nutritics® to quantify
total energy intake, macronutrients (carbohydrates, pro-
tein, fatty acids), n-3 and n-6 PUFA before and after the
supplementation period. In addition, at the start of the
supplementation period all participants were provided
with a food list with foods low (< 250 mg per serving),
moderate (~ 250 mg per serving) and high (> 500 mg per
serving) in omega-3 fatty acids to prevent increasing
their omega-3 intake through diet. Cut-off points were
used by USDA SR-21 (2008) [30].
EIMD protocol
Following a 3-min warm up, participants ran for 60 min
at the individualized predetermined Vtest at − 10% gradi-
ent. Heart rate (HR) and rating of perceived exertion
(RPE), Borg 6–20 scale [31] were recorded throughout
the trial every 10 min. A 60-s sample expired of gases
were collected at 20 and 40min of trial and analysed by
an on-line breath-by breath system for V̇O2 to ensure
participants were running at 65% V̇O2max. Water was
provided ad libitum every 15min whilst running. Imme-
diately after the muscle-damaging bout participants sat
and a blood sample was collected (post-EIMD). Partici-
pants then rated their perceived muscle soreness, and
MVIC and Wingate test were performed to assess par-
ticipants’ post-EIMD strength and power output,
respectively.
Venous plasma
A total of 12 mL of venous blood was collected at each
time point in two 6mL vacutainer tubes (K2 EDTA and
lithium-heparin; BD, Oxford, UK). Haematocrit with ca-
pillary method using a micro-hematocrit reader (Hawks-
ley & Sons Ltd., Lancing, UK) and haemoglobin
concentration using a photometer (Haemocue, Sheffield,
UK) were both analysed immediately on heparinized
whole blood in triplicate. Subsequently, concentration of
plasma markers was adjusted for plasma volume changes
with the method of Dill and Costill [32]. The remaining
whole blood was spun (Hettich Universal 320 R,
Germany) at 5000 rpm for 10min at 4 °C, with plasma
aliquoted and frozen at − 80 °C.
Circulating CK activity was measured using a clinical
chemistry analyser (Werfen ILab Aries, Italy). CK activ-
ity was determined using kinetic spectrophotometry at
340 nm with a minimum detection limit of 3 U/L, an un-
diluted linearity up to 900 U/L. Coefficient of variation
(CV) was within run < 1.2%, total < 2.5%. All samples
and standards were analysed in duplicate.
Aliquots of plasma were analysed for plasma IL-6 and
TNF-α concentration by enzyme-linked immunosorbent
assay (ELISA) DuoSet kits and ancillary reagent packs
(IL-6 DY206, TNF-α, DY210, consumables DY008, R&D
Systems, USA) in duplicate, according to manufacturer’s
instruction. Plates were read at 450 nm and blanked to
590 nm.
Perceived muscle soreness
Muscle soreness was self-rated by participants on a 10-
point-validated visual analogue scale (VAS) indicating
on a line from 0 (no pain) to 10 (extreme pain) [33],
during a wall squat with thighs parallel to the floor at
900 degrees.
Maximal voluntary isometric contraction
MVIC was assessed on a dynamometer (Globus Kineo
7000, Italy). The chair was adjusted so that the leg pad
was placed on the lower part of the tibialis anterior and
the pivot was located on the lateral epicondyle of the
right leg. Maximal force was measured at an angle of
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60o leg extension. Peak force was determined by the
average of four maximal isometric contractions lasting
3–5 s. The contraction time was recorded by an
experimenter.
Peak power
Participants performed a 10 s Wingate test on a cycle
ergometer (Monark Ergomedic 894E, Sweden), fixed
with an optical sensor (OptoSensor 2000™, Sport Medi-
cine Industries, USA) with the data obtained by the
Monark Anaerobic Test Software. Participants cycled
seated during the sprint protocol, with a resistance equal
to 7.5% of their body weight. Participants were verbally
encouraged throughout the test.
Statistical analysis
Normal distribution of all data was performed by the
Shapiro-Wilk Test. Following Levene’s test of equality of
variance, baseline characteristics, dietary and hydration
data were compared between groups using a two-tailed
independent samples t-test. The examination of the ef-
fect of the n-3 supplementation on plasma CK activity,
IL-6, TNF-α and DOMS was performed by non-
parametric tests, as these variables did not follow normal
distribution. Mann-Whitney U test was performed to
examine differences between N-3 and PLA group at each
time point. A Freidman test was used to determine the
main effect of time within-group and post hoc with Wil-
coxon Signed Rank tests (using a Bonferroni adjusted
alpha value) was run where a significant time was identi-
fied. MVIC and peak power data met all assumptions re-
quired for normality and were analysed using a two-way
mixed between-within participant repeated measures
analysis of variance (ANOVA). Bonferroni-adjust pair-
wise comparisons post hoc analysis was used where
needed to examine within subject differences. Values
were expressed as mean ± SD for data from parametric
tests and as median and interquartile range for data
from non-parametric tests. Statistical significance was
accepted as p < 0.05. Effect size was calculated using
methods proposed by Cohen [34], with effect sizes con-
sidered small (0.2), medium (0.5) or large (0.8). Statis-
tical analyses were performed using SPSS 25 software
(IBM SPSS, NY, USA). All figures were generated in
GraphPad Prism (Version 8, GraphPad).
Power calculation
The sample size was estimated from a sample calcula-
tion (G*Power 3.1) with an alpha level of 0.05, a power
(1-β) of 0.80 and a medium effect size of 0.5 and sug-
gests n = 12 in total would be sufficient.
Results
Descriptive characteristics
The physical characteristics of participants completed
EIMD are presented in Table 1. There was homogeneity
in all characteristics of participants between groups.
Descriptive characteristics in dietary data at baseline
(before supplementation) of participants from both
groups are presented in Table 2. An independent-
samples t-test was conducted to compare energy, macro-
nutrients and n-6/n-3 ratio between groups, and Mann-
Whitney U test was performed to compare n-3 intake
[N-3, Md = 7.57 (53.00); PLA, Md = 7.43 (52.00), U =
24.00, Z = − 0.064] and n-6 intake [N-3, Md = 8.21
(57.50); PLA, Md = 6.79 (47.50), U = 19.50, Z = − 0.640]
between groups. There was no significant difference in
food intake (p > 0.05) at baseline between N-3 and PLA
group (Table 2).
Descriptive characteristics in dietary data after the
supplementation period of participants from both groups
are presented in Table 3. An independent-samples t-test
was conducted to compare energy, macronutrients, n-3
and n-6 intake between groups. There was a significant
difference in n-3 intake with N-3 group showing a
higher n-3 intake post supplementation. However, there
was no significant difference in any other food intake
(p > 0.05) between groups (Table 3).
In addition, an independent-samples t-test was con-
ducted to compare participants’ hydration status before
EIMD between N-3 and PLA group. There was no sig-
nificant difference in hydration status [N-3, n = 7, (M =
1.015, SD = 0.007) and PLA, n = 7, (M = 1.012, SD =
0.007); t (12) = 0.72, p > 0.05, two-tailed] between
groups.
Blood markers
Friedman’s ANOVA suggested an effect of time on CK
activity for both PLA and N-3 groups (both p < 0.001),
with post hoc testing suggesting both groups were in-
creased at 24, 48 and 72 h relative to baseline (p < 0.05,
r = 0.63 indicating a medium effect size for all three time
points; Fig. 2.
A). However, there was no significant difference be-
tween PLA and N-3 at any timepoint.
Mann-Whitney U test was used to compare plasma
IL-6 concentration between N-3 and PLA group. There
was no significant difference between groups at any time
point. Nevertheless, Friedman’s ANOVA revealed
plasma IL-6 did not change over time in N-3 group (p =
0.434) but did change in PLA group (p = 0.009). Post
hoc testing suggested IL-6 was elevated in the PLA
group at immediately post-EIMD relative to baseline
(p < 0.05, r = 0.61 indicating a medium effect size) but
no other time points (Fig. 2)
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B). Mann-Whitney U test was performed to compare
plasma TNF-α concentration between groups. Plasma
TNF-α did not differ with time in either PLA (p = 0.274)
or N-3 group (p = 0.345; Fig. 2c).
Functional measurements
Mann-Whitney U test was run to compare perceived
muscle soreness between N-3 and PLA group at each
time point. There was a statistically significant difference
in DOMS between groups at 24 h post-EIMD, with PLA
showing a higher muscle soreness compared to N-3
group (p = 0.034) with a medium effect size (r = 0.56).
Friedman’s test suggested DOMS significantly differed
both within the N-3 and PLA group (p < 0.001). Pairwise
comparisons suggested that N-3 group had elevated
DOMS immediately post (r = 0.57) and at 24 h post-
EIMD (r = 0.59) relative to pre (all p < 0.05), whilst the
PLA group maintained DOMS for longer, being elevated
immediately post (r = 0.64), and at both 24 and 48 h
post-EIMD (r = 0.6) relative to pre (all p < 0.05; Fig. 3a).
No group x time interaction was noted for MVIC (re-
peated measures ANOVA, p = 0.813) or a main effect of
group (p = 0.338). A significant main effect for time was
observed for MVIC leg strength (p = 0.011, ηp
2 = 0.813).
This result suggests a large effect size with MVIC sup-
pressed relative to pre in both N-3 and PLA groups (N-
3 = 29.6 (±8.8) kg vs 20.8 (±10.6) kg, PLA = 36.5 (±10.2)
kg vs 27.1 (±7.4) kg; both p < 0.05) immediately post-
EIMD, but no other time points (Fig. 3b).
No group x time interaction was noted for peak power
(repeated measures ANOVA, p = 0.514) or a main effect
of group (p = 0.310). A significant main effect for time
was observed for peak power (p = 0.014, ηp
2 = 0.841).
This result suggests a large effect size with post hoc test-
ing suggesting no change in peak power following EIMD
in N-3 group, but a suppression in peak power in PLA
group at 24 h relative to pre [pre-EIMD = 825.6 (±90.7),
24 h = 763.0 (±103.1) W, p < 0.05] (Fig. 3c).
Discussion
Results presented here suggest that 4 weeks supplemen-
tation with 3 g/day of n-3 PUFA offsets the EIMD in-
duced pain response following a single bout of high
intensity exercise. Whilst a decreased peak power output
in PLA group at 24 h following EIMD and a blunted
time response in pro-inflammatory marker IL-6 was wit-
nessed in the N-3 group immediately post-EIMD, no be-
tween group differences were found. Although findings
suggest decreased MVIC and increased plasma CK fol-
lowing EIMD, no difference was observed between
groups, overall suggesting minimal positive gain in exer-
cise performance with n-3 supplementation.









Age (years) 25.07 (± 4.05) 25.57 (± 4.18) 24.57 (± 4.24) 0.66
Weight (kg) 73.04 (± 9.82) 69.34 (± 10.93) 76.74 (± 7.59) 0.17
Height (cm) 179.59 (± 10.24) 174.60 (± 11.64) 184.59 (± 5.77) 0.06
BMI (kg/m2) 22.60 (± 1.80) 22.63 (± 1.41) 22.59 (± 2.24) 0.97
Body fat (%) 10.75 (± 4.07) 10.40 (± 4.29) 11.10 (± 4.15) 0.76
V̇O2max (ml/kg/min) 62.43 (± 11.77) 65.11 (± 11.08) 59.74 (± 12.66) 0.41
Values are expressed as mean ± SD. N-3, omega-3 group; PLA placebo group, BMI body mass index, V̇O2max maximal oxygen consumption








Energy (Kcals) 2580.64 (± 789.39) 2664.71 (± 414.35) 2496.57 (± 1077.93) 0.707
CHO (g) 296.64 (± 83.62) 319.71 (± 59.15) 273.57 (± 102.02) 0.321
Protein (g) 109.11 (± 30.21) 108.64 (± 23.20) 109.57 (± 37.94) 0.957
Fat (g) 94.99 (± 46.12) 89.48 (± 28.06) 100.49 (± 61.23) 0.673
n-3 (g)a 1.56 (± 1.43) 1.41 (± 1.20) 1.70 (± 1.72) 0.949
n-6 (g)a 9.47 (± 7.42) 9.85 (± 6.59) 9.09 (± 8.69) 0.522
n-6/n-3 ratio 8.20 (± 4.91) 9.18 (± 4.81) 7.21 (± 5.18) 0.476
Values are expressed as mean ± SD. N-3 omega-3 group, PLA placebo, CHO carbohydrates, n-3 omega-3 fatty acids, n-6 omega-6 fatty acids. aindicate Mann-
Whitney U test
Kyriakidou et al. Journal of the International Society of Sports Nutrition            (2021) 18:9 Page 6 of 11
Blood markers
Our data show a significant increase of CK activity fol-
lowing EIMD before returning to baseline in both
groups, mirroring those previously reported [9, 35]. Con-
versely, Bloomer et al. [20] reported no significantly in-
creased CK activity following eccentric exercise. This
finding is in agreement with the findings by Atashak
et al. [19], another study [36] with a similar exercise
protocol, following a 40 min downhill running, and Tsu-
chiya et al. [23] after an eccentric protocol with a similar
dose but longer supplementation period (8 weeks).
The data presented here showed a large degree of vari-
ability in circulating CK (from 65 to 4939 U/L) which is
in accordance with previous research [37]. Hence, CK
alone might not be an accurate reflection of the degree
of muscle damage following eccentric exercise [38] due
to large inter-individual variability in response with a
range from 236 to 25,244 IU/L [1]. Therefore, the results
of the efficacy of the n-3 supplementation on indirect
muscle damage biomarkers, such as CK, following max-
imal exercise performance may be inconsistent due to
variability alone, and such markers should not be con-
sidered in isolation.
Plasma IL-6 concentration peaked immediately post-
EIMD for the PLA group. This peak of plasma IL-6 after
exercise is well documented in the literature [39–41].
However, there was no significant difference in plasma
IL-6 concentration between N-3 and PLA group. This
finding is in accordance with the findings by Tarbinian
et al. [41], who found no significant difference between
groups in plasma IL-6 concentration immediately post-
exercise.
In a manner similar to plasma IL-6, there were no dif-
ferences in post-EIMD plasma TNF-α concentration be-
tween N-3 and PLA groups. There is conflicting
evidence about the behaviour of TNF-α response after
muscle-damaging exercise. Toft et al. [42] have shown
that plasma TNF-α was elevated after prolonged exer-
cise, others did not observe any change [43] and others
recorded a decrease in the TNF-α [44]. In the study by
Lenn et al. [45], TNF-α was not significantly increased,
which is a similar result with the present study, where
no significant increase was demonstrated in plasma
TNF-α concentration. This could be due to a feedback
mechanism, that IL-6 inhibits TNF-α [43]. Thus, it may
be that plasma TNF-α is not an optimal marker to quan-
tify EIMD-induced inflammation.
Functional measurements
We report a significant change in VAS pain score fol-
lowing EIMD in both groups, further evidence that the
exercise protocol used caused significant muscle dam-
age. More specifically, participants’ pain perception
peaked immediately post-EIMD and remained elevated
at 24–48 h post-EIMD, which is consistent with other
findings [1, 46]. Our study demonstrated a significant
difference in perceived muscle soreness between groups
at 24 h post-EIMD, suggesting N-3 may have experi-
enced less pain compared to PLA group at this point.
Previous studies [17, 18, 47] also found significant differ-
ences in DOMS between groups following EIMD, with
the fish oil group having reduced muscle soreness. On
the contrary, Jakeman et al. [17] an acute dose of n-3
PUFA immediately after a muscle-damaging exercise,
demonstrated similar muscle soreness between groups.
The absence of effect on DOMS might be due to the acute
supplementation dose following exercise and is insuffi-
cient to change muscle phospholipid content [48, 49] rela-
tive to the 4 weeks of supplementation used here.
Subsequent exercise performance is significantly affected
by EIMD and its symptoms [2]. The loss of muscle force is
considered the most valid indirect measurement of muscle
damage [50]. As expected, and when observing a large ef-
fect size, the leg strength significantly decreased immedi-
ately post-EIMD in both groups compared with pre-EIMD
values. However, there were no significant differences in
MVIC between groups nor was any interaction effect ob-
served, suggesting that levels of muscle damage were
Table 3 Dietary data post supplementation (+ 3 g of n-3 supplementation) of participants completed EIMD, independent sample t-








Energy (Kcals) 2574.57 (± 928.64) 2653.43 (± 794.99) 2495.71 (± 1105.43) 0.765
CHO (g) 305.64 (± 134.93) 293.50 (± 68.18) 317.78 (± 185.62) 0.751
Protein (g) 109.79 (± 32.36) 104.06 (± 26.08) 115.52 (± 38.89) 0.529
Fat (g) 92.84 (± 37.37) 104.33 (± 38.87) 81.35 (± 34.74) 0.266
n-3 (g) 2.82 (± 1.92) 3.87 (± 1.90) 1.78 (± 1.34) 0.036*
n-6 (g) 8.47 (± 5.41) 8.65 (± 5.83) 8.29 (± 5.42) 0.906
n-6/n-3 ratio 4.65 (± 3.80) 3.19 (± 3.18) 6.12 (± 4.03) 0.157
*Significant level, p < .05; Values are expressed as mean ± SD. N-3 omega-3 group, PLA placebo, CHO carbohydrates, n-3 omega-3 fatty acids, n-6 omega-6
fatty acids
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Fig. 2 Plasma markers of muscle damage and inflammation as a
function of time. a CK (% change from baseline), b IL-6 (% change from
baseline), and c TNF-α (% change from baseline). Data shown as
medians, error bars indicate interquartile range. Dashed horizontal line
indicates 100% (baseline). * indicates significant difference from baseline.
Time matched data points offset horizontally to enhance clarity
Fig. 3 Muscle functional measures prior (pre) and following (post –
72 h) EIMD. a DOMS, data indicates median, error bars interquartile
range. Both b MVIC (Kg), and c peak power (W) data indicate means,
error bars standard deviation. * indicates significant difference from
Pre timepoint, # indicates difference between groups at timepoint
indicated. Time matched data points offset horizontally to
enhance clarity
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unchanged by n-3 consumption. These findings match both
those of Gravina et al. [51], who reported no impact of 4
weeks of n-3 supplementation on leg strength, despite a
higher dose (equivalent of 0.1 g/kg/day of supplement in
capsules, 1000mg n-3 PUFA per capsule, with a mean in-
take of 7 ± 2 capsules per day) and of Gray et al. [20] who
showed no group effect, with a longer duration (6 weeks) of
n-3 supplementation. In addition, a very recent study by
Ramos-Campo et al. [52], examining muscle damage after
eccentric exercise, found no significant difference in
strength deficit between the supplementation and placebo
group following a 10-week n-3 supplementation. Therefore,
the implications of the findings from the previous studies
and ours are that n-3 supplementation does not have sig-
nificant positive effects on muscle strength recovery.
As a secondary measure of muscle function, we examined
cycling peak power, with no significant difference between
groups. However, the PLA group demonstrated a signifi-
cant suppression in peak power at 24 h following EIMD
relative to pre, while there was no change in N-3 group
relative to pre-EIMD. Decreased cycling peak power output
24 h following EIMD is in line with previous research [53].
The potential for preservation of voluntary peak power out-
put will be of interest to athletes where repeated maximal
powerful performance is required, which is reinforced by
differences in perceived pain at this timepoint.
In addition, we examined participants’ hydration status
before EIMD to ensure they began exercise euhydrated,
to prevent hydration being a cofounding factor for exer-
cise performance. We also assessed n-3 intake using a
48-h food diary at pre- and post-supplementation
period. No difference in n-3 intake was noted between
groups prior to supplementation. As it would be ex-
pected, there was an increase in n-3 intake in the N-3
group relative to the PLA group after supplementation.
Limitations, recommendations and future directions
Some potential limitations of the present study should
be acknowledged. Low statistical power due to the mod-
est sample size played a role in limiting the significance
of the statistical comparisons conducted. The strict inclusion
criteria as well as the downhill running task performance
made recruitment for participants difficult. Additional blood
biomarkers, such as myoglobin and C-reactive protein, may
also provide further information in future studies on muscle
damage. A clearer picture on change in muscle function
could involve examining n-3 supplementation and muscle
damage considering multiple functional measurements, such
as MVC torque at multiple joint angles, ROM, limb swelling
and/or jump height. Measurements of muscle function
should be used in combination with indirect plasma markers
to provide more reliable evidence in assessing the magnitude
of muscle damage. Ideally, directly measuring muscle dam-
age from muscle biopsies would be optimal, albeit highly
invasive. Additionally, future studies may consider taking
blood samples at additional acute time points, such as 1, 3, 6
or 12 h after the muscle-damaging exercise. By doing so, we
might have observed an acute inflammatory response differ-
ence between groups, as has been observed elsewhere [17].
Participants’ diets were not explicitly controlled during the
4-week loading period, however, a 48-h food diary was re-
corded immediately before supplementation period and re-
peated 48 h before supplementation finished (immediately
before EIMD); results of which suggested participants did
not change their habitual macronutrient or total caloric in-
take. Future studies may consider a method to control par-
ticipants’ food intake, such as providing pre-packaged meals
or recording complete food diaries throughout both supple-
mentation period and recovery phase. However, this would
incur both significant cost and require participants to have a
greater commitment to these methods. In an attempt to iso-
late the effect of n-3 supplementation, collagen was chosen
as the placebo in this study to avoid manipulation of n-6/n-
3 ratio. There is no evidence in the literature that collagen
has a pro or anti-inflammatory effect, and therefore, it would
not oppose the action of n-3 supplementation. Whereas,
other reports have utilized corn oil as a placebo control
which is high in n-6, and thus may not represent a true pla-
cebo [11, 54].
Conclusion
Overall, these findings support the hypothesis that 4 weeks
of 3 g/day n-3 supplementation may attenuate minor as-
pects of EIMD, as observed in DOMS and peak power.
Typically, no significant differences were noted between
groups, however, it was observed a blunted inflammatory
response immediately after eccentric exercise and a de-
creased CK activity at 24 h following muscle-damaging ex-
ercise in N-3 group. There were also no significant
differences in leg strength between groups indicating that
n-3 supplementation will have limited impact on muscle
function and subsequent performance. Whilst not improv-
ing performance, these findings may have relevance to
soreness-associated exercise avoidance.
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ANOVA: Analysis of variance; AA: Arachidonic acid; BIA: Bioelectrical
impedance analysis; BMI: Body mass index; CK: Creatine kinase;
CV: Coefficient of variation; DHA: Docosahexaenoic acid; DOMS: Delayed-
onset muscle soreness; EIMD: Exercise-induced muscle damage;
ELISA: Enzyme-linked immunosorbent assay; EPA: Eicosapentaenoic acid;
Hb: Haemoglobin; Hct: Haematocrit; HR: Heart rate; IL-1ra: Interleukin-1
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receptor; IL-6: Interleukin-6; IL-10: Interleukin-10; MVIC: Maximal voluntary
isometric contraction; n-3 PUFA: Omega-3 polyunsaturated fatty acids; N-
3: Omega-3 interventional group; PAR-Q: Physical activity readiness
questionnaire; PLA: Placebo group; Post-EIMD: Following exercise-induced
muscle damage; Pre-EIMD: Before exercise-induced muscle damage;
ROM: Range of motion; ROS: Reactive oxygen species; RPE: Rating of
perceived exertion; RPM: Revolutions per minute; SD: Standard deviation;
TNF–α: Tumor necrosis factor–alpha; USG: Urine specific gravity; VAS: Visual
analogue scale; V̇O2: Absolute oxygen consumption; V̇O2max: Maximal
oxygen consumption; Vtest: Downhill running speed; WURSS: Wisconsin
upper respiratory symptom survey
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